|Table of Contents|

Research progress on the improvement of ALC/AMC ratio in DLBCL treated with lenalidomide combined with R-CHOP

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2023 13
Research Field:
Publishing date:


Research progress on the improvement of ALC/AMC ratio in DLBCL treated with lenalidomide combined with R-CHOP
HOU YangyangLIU Aichun
Department of Hematology and Lymphology,Affiliated Tumor Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China.
diffuse large B-cell lymphomalenalidomideALC/AMCprognosis
Diffuse large B-cell lymphoma (DLBCL) is the major subtype of non-Hodgkin lymphoma.DLBCL is different in clinical manifestation,gene expression,treatment response and prognosis.The ratio of peripheral lymphocyte cells to monocytes (ALC/AMC) is a surrogate index for host immunity and tumor microenvironment,it is a biomarker for predicting the clinical outcome of patients with DLBCL.Lenalidomide is an immunomodulatory drug that is effective in DLBCL patients and has multiple mechanisms of action on tumor microenvironment and host immune response.In this review,the adverse prognostic value of ALC/AMC ratio appears to be overcome by lenalidomide combined with standard R-CHOP in previously untreated DLBCL patients.


[1] SEHN LH,SALLES G.Diffuse large B-cell lymphoma[J].N Engl J Med,2021,384(9):842-858.
[2] WRIGHT GW,HUANG DW.A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J].Cancer Cell,2020,37(4):551-568.
[3] CABANILLAS F,SHAH B.Advances in diagnosis and management of diffuse large B-cell lymphoma [J].Clinical Lymphoma Myeloma and Leukemia,2017,17(12):783-796.
[4] XIA WK,LIN QF,SHEN D,et al.Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma:a systematic review and meta-analysis [J].FEBS Open Bio,2016,6(6):558-565.
[5] CASTELLINO A,PEDERSON LD,RISTOW KM,et al.Lenalidomide in combination with standard R-CHOP overcomes the negative prognostic value of peripheral blood absolute lymphocyte/monocyte ratio at diagnosis and during treatment in patients with diffuse large B-cell lymphoma [J].Blood,2018,132(Suppl 1):4139.
[6] OTT G,ZIEPERT M,KLAPPER W,et al.Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL[J].Blood,2010,116(23):4916-4925.
[7] DE GROEN RAL,SCHRADER AMR,KERSTEN MJ,et al.MYD88 in the driver's seat of B-cell lymphomagenesis:from molecular mechanisms to clinical implications [J].Haematologica,2019,104(12):2337-2348.
[8] DAVIS RE,NGO VN,LENZ G,et al.Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma [J].Nature,2010,463(7277):88-92.
[9] PASQUALUCCI L,ZHANG B.Genetic drivers of NF-κB deregulation in diffuse large B-cell lymphoma [J].Seminars in Cancer Biology,2016,39:26-31.
[10] PASQUALUCCI L,DALLA-FAVERA R.Genetics of diffuse large B-cell lymphoma [J].Blood,2018,131(21):2307-2319.
[11] DE MIRANDA NF,GEORGIOU K,CHEN L,et al.Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients [J].Blood,2014,124(16):2544-2553.
[12] SNEERINGER CJ,SCOTT MP,KUNTZ KW,et al.Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas [J].Proc Natl Acad Sci USA,2010,107(49):20980-20985.
[13] MORIN RD,ASSOULINE S,ALCAIDE M,et al.Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas [J].Clin Cancer Res,2016,22(9):2290-2300.
[14] VERMAAT JS,SOMERS SF,DE WREEDE LC,et al.MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis [J].Haematologica,2020,105(2):424-434.
[15] SEHN LH,BERRY B,CHHANABHAI M,et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J].Blood,2007,109(5):1857-1861.
[16] NYMAN H,JERKEMAN M,KARJALAINEN-LINDSBERG ML,et al.Bcl-2 but not FOXP1,is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas [J].Eur J Haematol,2009,82(5):364-372.
[17] YOON DH,CHOI DR,AHN HJ,et al.Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP[J].Eur J Haematol,2010,85(2):149-157.
[18] MORTON LM,SLAGER SL,CERHAN JR,et al.Etiologic heterogeneity among non-Hodgkin lymphoma subtypes:the InterLymph Non-Hodgkin Lymphoma Subtypes Project [J].J Natl Cancer Inst Monogr,2014,2014(48):130-144.
[19] KIM DH,BAEK JH,CHAE YS,et al.Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma [J].Leukemia,2007,21(10):2227-2230.
[20] FRUEHAUF S,TRICOT G.Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes [J].Biol Blood Marrow Transplant,2010,16(12):1629-1648.
[21] WILCOX RA,WADA DA,ZIESMER SC,et al.Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells [J].Blood,2009,114(14):2936-2944.
[22] PORRATA LF,RISTOW K,COLGAN JP,et al.Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma [J].Haematologica,2012,97(2):262-269.
[23] SUN F,ZHU J,LU S,et al.An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era [J].BMC Cancer,2018,18(1):5.
[24] WILCOX RA,RISTOW K,HABERMANN TM,et al.The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma [J].Leukemia,2011,25(9):1502-1509.
[25] WATANABE R,TOMITA N,ITABASHI M,et al.Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era [J].Eur J Haematol,2014,92(3):204-210.
[26] PORRATA LF,INWARDS DJ,ANSELL SM,et al.Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma [J].Biol Blood Marrow Transplant,2014,20(11):1804-1812.
[27] REDDY N,HERNANDEZ-ILIZALITURRI EJ,DEEB G,et al.Immunomodulatory drugs stimulate natural killer-cell function,alter cytokine production by dendritic cells,and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo[J].British Journal of Haematology,2007,140(1):36-45.
[28] ZHU YX,BRAGGIO E,SHI CX,et al.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide [J].Blood,2011,118(18):4771-4779.
[29] DALL' OZZO S,TARTAS S,PAINTAUD G,et al.Rituximab-dependent cytotoxicity by natural killer cells:influence of FCGR3A polymorphism on the concentration-effect relationship [J].Cancer Research,2004,64(13):4664-4669.
[30] LU L,PAYVANDI F,WU L,et al.The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions [J].Microvascular Research,2009,77(2):78-86.
[31] VITOLO U,CHIAPPELLA A,FRANCESCHETTI S,et al.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma:results of the REAL07 open-label,multicentre,phase 2 trial[J].The Lancet Oncology,2014,15(7):730-737.
[32] COIFFIER B,THIEBLEMONT C,VAN DEN NESTE E,et al.Long-term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d' Etudes des Lymphomes de l'Adulte [J].Blood,2010,116(12):2040-2045.


Last Update: 2023-05-31